

Anti-RSV (Palivizumab), Humanized Antibody

07/20

CATALOG NO.: A2166-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG1 kappa monoclonal antibody that is produced by recombinant DNA technology. The antibody is used to prevent RSV infections. RSV is a non-segmented, enveloped, single-stranded, negative-sense virus that is known to cause mild lower respiratory tract infections in infants. The antibody specifically targets an epitope in the antigenic A site (between amino acids 258 and 275) of the RSV fusion glycoprotein and prevents the entry of the virus inside the host cell. The antibody is composed of 95% human and 5% murine antibody sequences. It consists of two heavy chains and two light chains and has a molecular weight of 148 kDa. The original drug received FDA approval to treat prophylaxis in children. It is also recommended to infants who are at high risk, either due to premature birth, or medical problems such as congenital heart disease and bronchopulmonary dysplasia (BPD).

ALTERNATE NAMES: Human Respiratory Syncytial Virus, HRSV, MEDI 493, MEDI-493

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human RSV

CAS NUMBER: 188039-54-5

MOLECULAR WEIGHT: 147.7 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)

Anti-RSV (Felvizumab), Human IgG1 Antibody (A1446)

Anti-IgE (Omalizumab), Humanized Antibody (A2145)

Anti-Flavivirus group antigen, Human IgG1 Antibody (A1102)

Anti-VEGF (Bevacizumab), Humanized Antibody (A1045)

FOR RESEARCH USE ONLY! Not to be used on humans.